Consequently, DCs can process foreign NeoAgs through two distinct pathways: presentation via MHC II to CD4+ T cells, or translocation into the cytosol for entry into the MHC I processing pathway, which enables “cross-presentation” to CD8+ T cells that are specialized for tumor recognition [15]. The gene discussed is CD8A; the disease is neoplasm.